Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Teva ponies up $160M-plus for marketing rights to Celltrion's Rituxan, Herceptin biosims
Teva ponies up $160M-plus for marketing rights to Celltrion's Rituxan, Herceptin biosims
Teva ponies up $160M-plus for marketing rights to Celltrion's Rituxan, Herceptin biosims
Submitted by
admin
on October 7, 2016 - 9:11am
Source:
Fierce Pharma
News Tags:
Teva Pharmaceutical
Celltrion
Rituxan
Herceptin
biosimilars
Headline:
Teva ponies up $160M-plus for marketing rights to Celltrion's Rituxan, Herceptin biosims
Do Not Allow Advertisers to Use My Personal information
